News and Media Coverage

Urologist access to prostate-specific membrane antigen (PSMA)-targeting agents is high among US practitioners, results of an exclusive Urology Times survey indicate. In total, 88% of respondents said they can order PSMA scans locally, with 9% saying they could not, and [...]

In this interview, Jason M. Hafron, MD, discusses the ECLIPSE trial evaluating 177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer. Hafron is the chief medical officer and medical director of clinical research at the Michigan Institute of Urology, PC, and a professor of [...]

Michigan Institute of Urology (MIU), one of the longest-standing and largest sub-specialty urology practices in Southeast Michigan, has been activated as a clinical trial site for Francis Medical's interventional study on water vapor ablation for localized intermediate-risk prostate cancer. The [...]

While physicians are working hard to see many patients and keep their practices profitable, there's an insidious underlying problem that saps/sabotages/drains their major efforts: staff shortages that prevent them from efficient work, and perhaps even from billing for the work [...]

The American Cancer Society predicts that by the end of 2023, nearly 35,000 deaths will be caused by prostate cancer. It's the second leading cause of cancer death in American men. On Father's Day, the Detroit Zoo is where the [...]